The pharmacodynamics profile for 13.2-mg IN epinephrine in the opposite or same nostrils was comparable to that of the 0.3-mg autoinjector and 0.5-mg manual syringe. Intranasal (IN) epinephrine is ...

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Please provide your email address to receive an email when new articles are posted on . Subjects had two doses each of Belhaven Biopharma’s BBP01 and intramuscular epinephrine. Subjects had faster and ...

The designation is supported by data from Part 1 of the EPIPHAST study, which compared the pharmacokinetics and pharmacodynamics of AQST-109 to intramuscular epinephrine in healthy adults. The Food ...

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular ...

RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven Biopharma, a leader in developing innovative intranasal products for emergency use, today announced that the U.S. Food and Drug ...

LOUISVILLE, Ky. -- A sublingual film may be able to deliver epinephrine as effectively as intramuscular injections and provide an alternate pathway for urgent treatment of allergic anaphylaxis, a ...

Please provide your email address to receive an email when new articles are posted on . Many patients fail to carry or use their autoinjectors because they are afraid of needles. NDS1C epinephrine ...

WARREN, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and ...

Epinephrine now available in a nasal spray formulation (neffy) is being hailed as a way to diminish barriers to use, which is critical in emergency situations such as an anaphylactic reaction. The ...

The MarketWatch News Department was not involved in the creation of this content. Belhaven's Investigational New Drug (IND) Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ...